125 related articles for article (PubMed ID: 19164417)
1. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.
Turkova A; Ball C; Gilmour-White S; Rela M; Mieli-Vergani G
J Antimicrob Chemother; 2009 Mar; 63(3):623-5. PubMed ID: 19164417
[No Abstract] [Full Text] [Related]
2. Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.
Elsharkawy AM; Schwab U; McCarron B; Burt AD; Daly AK; Hudson M; Masson S
J Clin Virol; 2013 Sep; 58(1):331-3. PubMed ID: 23763943
[TBL] [Abstract][Full Text] [Related]
3. Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.
Tommasi C; Ceccherini-Silberstein F; D'Arrigo R; Bellagamba R; Tempestilli M; Dessì C; Santoro MM; Forbici F; Nicastri E; Pucillo LP; Perno CF; Narciso P
Scand J Infect Dis; 2010 Mar; 42(3):237-9. PubMed ID: 20085429
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring.
Fink DL; Bloch E
Int J STD AIDS; 2013 Oct; 24(10):831-3. PubMed ID: 23970595
[TBL] [Abstract][Full Text] [Related]
5. Interaction between antiretroviral drugs and acenocoumarol.
Welzen ME; van den Berk GE; Hamers RL; Burger DM
Antivir Ther; 2011; 16(2):249-52. PubMed ID: 21447874
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
7. Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature.
Lopez-Delgado JC; Mendiluce RM; Pinol TS; Fernández XP; Sanchez L; Vicente RG
Ann Transplant; 2012; 17(1):122-7. PubMed ID: 22466918
[TBL] [Abstract][Full Text] [Related]
8. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
[No Abstract] [Full Text] [Related]
10. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Cordery DV; Hesse K; Amin J; Cooper DA
Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
[TBL] [Abstract][Full Text] [Related]
12. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
14. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
15. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
[TBL] [Abstract][Full Text] [Related]
17. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C
J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773
[No Abstract] [Full Text] [Related]
18. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
[No Abstract] [Full Text] [Related]
19. Experience with efavirenz in end-stage renal disease.
Prime KP; Woolfson RG; Pakianathan MR
Int J STD AIDS; 2003 Jul; 14(7):497-8. PubMed ID: 12869233
[TBL] [Abstract][Full Text] [Related]
20. Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.
Cattaneo D; Ripamonti D; Gervasoni C; Landonio S; Meraviglia P; Baldelli S; Cozzi V; Fucile S; Clementi E
J Clin Pharmacol; 2012 Mar; 52(3):440-5. PubMed ID: 21383337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
